profit from every $100 of sales.
$0$100
Castle Biosciences
$33.79-2.06% today
-1.0% in 1 year
1-year low $18.151-year high $43.04
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Castle Biosciences sold, what it kept, and what it did with the cash.
Sales went from $137 million in 2022 to $344 million in 2025, with -$24.2 million of profit last year.
SalesProfit
Castle Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Castle Biosciences | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Castle Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 137 | 220 | 332 | 344 | |
| 105 | 175 | 272 | 273 | |
| -91 | -68 | 9 | -43 | |
| -58 | -45 | 38 | 11 | |
| -67 | -57 | 18 | -24 | |
| -2.58 | -2.14 | 0.62 | -0.83 | |
| 76.6% | 79.5% | 81.9% | 79.4% | |
| -66.5% | -30.9% | 2.6% | -12.4% | |
| -49.0% | -26.1% | 5.5% | -7.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 447 | 453 | 531 | 579 |
| Cash | 123 | 99 | 120 | 117 |
| Total debt | 13 | 15 | 26 | 37 |
| Total liabilities | 48 | 62 | 75 | 108 |
| 399 | 391 | 456 | 471 | |
| 26 | 27 | 29 | 29 | |
| -13.2% | -11.1% | 3.6% | -4.6% | |
| -16.8% | -14.7% | 4.0% | -5.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -42 | -6 | 65 | 64 | |
| 6 | 14 | 28 | 36 | |
| -47 | -19 | 37 | 28 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 36 | 51 | 50 | 46 |
Valuation
- –
- –
- –
- 1.2×
- 3.0×
- 36.8×
- 84.8×
- 2.7%
- -2.3%
- 0.0%
Profitability
- 79.4%
- -12.4%
- -7.0%
- -1.4%
- -4.8%
- -7.8%
- -2.8%
- -2.3%
- -6.7%
- 15.8%
Growth
- +35.9%
- –
- −22.5%
- –
- +3.6%
Financial health
- 5.6×
- 0.08
- 6.7%
- -164.0×
- 6.75
- 6.53
- 0.62
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 31%of 946
Bottom 14%of 872
Top 16%of 868
Top 37%of 986
What analysts expect
- Average price target
- $47.80
- Range
- $40.00 – $52.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.49 | -0.49 | +0.0% |
| Feb 26, 2026 | -0.08 | -0.23 | +65.2% |
| Nov 3, 2025 | -0.02 | -0.34 | +94.1% |
| Aug 4, 2025 | 0.15 | -0.51 | +129.4% |
| May 5, 2025 | -0.20 | -0.08 | −150.0% |
| Feb 27, 2025 | 0.32 | -0.04 | +900.0% |
| Nov 4, 2024 | 0.08 | -0.06 | +233.3% |
| Aug 5, 2024 | 0.31 | -0.27 | +214.8% |
News
Castle Biosciences signals $385M-$395M 2026 revenue outlook as TissueCypher targets 50%-52% volume growthSeeking Alpha · Nov 6, 2026Crown Castle trades lower despite Q3 beat, 2026 guidance boost on lower revenueSeeking Alpha · Oct 21, 2026Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and MoreYahoo Finance · Aug 20, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
65Pass
Philip Fisher
42No pass
Peter Lynch
73Pass
Joel Greenblatt
2No pass
Charlie Munger
25No pass
Terry Smith
26No pass
Questions about Castle Biosciences
Is Castle Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Castle Biosciences AI analysis
What does Castle Biosciences do?
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. It is in Medical - Diagnostics & Research.
Does Castle Biosciences pay a dividend?
No. Castle Biosciences does not pay a dividend at the moment.
Is Castle Biosciences stock halal?
Yes. Castle Biosciences passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
How has Castle Biosciences stock done over the past year?
Down 1.0% over the past twelve months, to $33.79. It traded between $18.15 and $43.04 and is 21.5% below its high.
Who are Castle Biosciences's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Castle Biosciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.